ACR Convergence 2021

November 5-9, 2021. All Virtual.

View by Number View by Title View Sessions

View by Date

Tuesday, November 9, 2021

8:30AM-10:30AM: Abstract Number: 1541

Preliminary Criteria for Macrophage Activation Syndrome Associated with Coronavirus Disease-19

Infection-related Rheumatic Disease Poster (1530–1564)

8:30AM-10:30AM: Abstract Number: 1614

Preliminary Results from a Pilot Feasibility and Acceptability Trial of Resilience Coaching for Adolescent Chronic Musculoskeletal Pain

Pediatric Rheumatology – Clinical Poster III: Miscellaneous Rheumatic Disease (1614–1644)

8:30AM-10:30AM: Abstract Number: 1841

Presence of Autoantibodies to Dense-Fine-Speckled 70 (DFS70) Do Not Necessarily Rule out Connective Tissue Diseases

Systemic Sclerosis & Related Disorders – Clinical Poster III (1836–1861)

8:30AM-10:30AM: Abstract Number: 1785

Prevalence and Incidence of PsA in Germany – a Cohort Study with 65 Million Participants

Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster IV: Clinical Aspects of PsA & Peripheral SpA (1773–1800)

8:30AM-10:30AM: Abstract Number: 1517

Prevalence of Autoantibodies in Patients with Melanoma Who Develop Rheumatic Immune Related Adverse Events During Treatment with Immune Checkpoint Blockade

Immunological Complications of Therapy Poster (1516–1529)

8:30AM-10:30AM: Abstract Number: 1561

Prevalence of SARS-CoV2 Infection in Diseases Inflammatory Rheumatology in the Rheumatology Service of the Hospital Docente Padre Billini, Dominican Republic

Infection-related Rheumatic Disease Poster (1530–1564)

8:30AM-10:30AM: Abstract Number: 1515

Programmed Cell Death Protein 1 (PD-1)-Expressing CD4+ T Cells Are Expanded in Early Rheumatoid Arthritis and Correlate with Response to Treatment

T Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster (1507–1515)

8:30AM-10:30AM: Abstract Number: 1715

Providing High Quality Family Care Planning for Women with Rheumatic Disease in Rheumatology Clinics: Perspectives of Rheumatology Clinicians

Reproductive Issues in Rheumatic Disorders Poster (1711–1731)

8:30AM-10:30AM: Abstract Number: 1791

Psoriasis Onset Before Rheumatic Symptoms in Patients with Spondyloarthritis: Does It Relate to Clinical Characteristics and the Rheumatologist’s Diagnosis? Data from REGISPONSER Registry

Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster IV: Clinical Aspects of PsA & Peripheral SpA (1773–1800)

8:30AM-10:30AM: Abstract Number: 1827

Psoriatic Arthritis, Female Sex and Increased Baseline Skin Severity Are Associated with Drug Persistence in Ustekinumab-Treated Patients with Psoriasis in the BADBIR Cohort

Spondyloarthritis Including PsA – Treatment Poster III: Psoriatic Arthritis II (1801–1835)

8:30AM-10:30AM: Abstract Number: 1503

Putting the Pieces on the Board: Mapping SLE Nephritis Biopsies from the Accelerating Medicines Project Using High-Density Immunofluorescence Imaging

SLE – Etiology & Pathogenesis Poster (1480–1506)

8:30AM-10:30AM: Abstract Number: 1548

Q Fever as a Mimicker of Rheumatologic Conditions: A Case Series from Two Tertiary Care Academic Centers in Southern California

Infection-related Rheumatic Disease Poster (1530–1564)

8:30AM-10:30AM: Abstract Number: 1780

Racial Disparities in Comorbidities of Patients with Psoriatic Arthritis

Spondyloarthritis Including PsA – Diagnosis, Manifestations, & Outcomes Poster IV: Clinical Aspects of PsA & Peripheral SpA (1773–1800)

8:30AM-10:30AM: Abstract Number: 1815

Randomised, Double-blind, Placebo-controlled Study of Iguratimod in the Treatment of Active Spondyloarthritis

Spondyloarthritis Including PsA – Treatment Poster III: Psoriatic Arthritis II (1801–1835)

8:30AM-10:30AM: Abstract Number: 1884

Real-life Data for the Use of Anti-TNF Treatment in DADA2

Vasculitis – Non-ANCA-Associated & Related Disorders Poster II (1862–1888)

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].